Suven Pharmaceuticals Limited

Suven Pharmaceuticals Limited, headquartered in India, reported Scope 1 emissions of 41,183,000 kg CO2e and Scope 2 emissions of 22,941,000 kg CO2e for 2024. In 2023, the company's Scope 1 emissions were 48,594,000 kg CO2e and Scope 2 emissions were 33,723,000 kg CO2e. For 2022, both Scope 1 and Scope 2 emissions were reported as 48,594,000 kg CO2e and 33,723,000 kg CO2e, respectively.

Suven Pharmaceuticals Limited has committed to ambitious climate targets. They aim for a 15% reduction in CO2 emissions per metric tonne produced for both Scope 1 and Scope 2 between 2023 and 2025.

The company has also set Science Based Targets initiative (SBTi) validated targets. For near-term, Suven Pharmaceuticals Limited commits to reduce absolute Scope 1 and Scope 2 greenhouse gas emissions by 54.6% by FY2033 from a FY2023 base year. They also commit to reduce absolute Scope 3 GHG emissions by 54.6% within the same timeframe. For long-term, Suven Pharmaceuticals Limited aims to reduce absolute Scope 1 and Scope 2 GHG emissions by 90% by FY2050 from a FY2023 base year, with a corresponding 90% reduction in absolute Scope 3 GHG emissions within the same period. The company is committed to reaching net-zero greenhouse gas emissions across the entire value chain by FY2050. These targets are consistent with reductions required to keep global warming to 1.5°C.